Efficacy of Second-Generation FLT3 Inhibitors in FLT3-Mutated AML: A Meta-Analysis of Randomized Controlled Trials
Acta Haematologica · 19.06.2026 · 1-12
DOI: 10.1159/000553180 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Acta Haematologica, online erschienen am 19.06.2026. Verfasst von Qili Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Emergency Medical Center, Ningbo Hospital of Integrated Traditional Chinese and Western Medicine, Ningbo, China. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Introduction
Second-generation FLT3 inhibitors have demonstrated clinical efficacy in FLT3-mutated acute myeloid leukemia (AML), although results across randomized trials remain inconsistent. This meta-analysis aimed to evaluate the efficacy of second-generation FLT3 inhibitors in patients with FLT3-mutated AML.
Methods
We systematically searched databases including PubMed, Web of Science, and the Cochrane Library (from inception to August 2025) to identify randomized controlled trials (RCTs) evaluating second-generation FLT3 inhibitors for treating FLT3-mutated AML. The primary endpoints were overall survival (OS) and progression-free survival (PFS). A random-effects model was used to calculate pooled hazard ratios (HRs) and their 95% confidence intervals (95% CIs). The study protocol was registered in PROSPERO (CRD420251132477).
Results
This meta-analysis included eight RCTs involving 2,231 patients. The second-generation FLT3 inhibitors evaluated were gilteritinib and quizartinib, and control treatments included placebo or active non-FLT3-inhibitor regimens. Patients treated with second-generation FLT3 inhibitors exhibited significant improvements in both OS (HR: 0.72, 95% CI: 0.62–0.84; p < 0.001) and PFS (HR: 0.73, 95% CI: 0.63–0.86; p < 0.001). Subgroup analysis revealed that gilteritinib showed improvements in both OS (HR: 0.71, p = 0.001) and PFS (HR: 0.71, p < 0.001), and quizartinib significantly improved OS (HR: 0.72, p = 0.013) with no significant difference in PFS (HR: 0.75, p = 0.142). Among patients with newly diagnosed AML, second-generation FLT3 inhibitors did not significantly improve PFS (HR: 0.73, p = 0.127) but significantly improved OS (HR: 0.80, p = 0.037). Among patients with relapsed/refractory AML, significant benefits were observed in both OS (HR: 0.67, p < 0.001) and PFS (HR: 0.74, p = 0.04). Benefits were observed across both placebo-controlled and active-comparator trials.
Conclusion
Second-generation FLT3 inhibitors significantly improve survival outcomes in FLT3-mutated AML, particularly for gilteritinib and in relapsed/refractory disease. Further studies are needed to clarify mutation subtype-specific and dose-specific effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Emergency Medical Center, Ningbo Hospital of Integrated Traditional Chinese and Western Medicine, Ningbo, China.
- The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
- The Fifth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
- The Second School of Clinical Medical, Zhejiang Chinese Medical University, Hangzhou, China.
- Emergency Medical Center, Ningbo Hospital of Integrated Traditional Chinese and Western Medicine, Ningbo, China, qiuyixian2025@163.com.
Zitieren
APA
Yu, Q., Cao, J., Chen, Y., Ma, X., Hu, K., & Qiu, Y. (2026). Efficacy of Second-Generation FLT3 Inhibitors in FLT3-Mutated AML: A Meta-Analysis of Randomized Controlled Trials. Acta Haematologica, 1-12. https://doi.org/10.1159/000553180
Vancouver
Yu Q, Cao J, Chen Y, Ma X, Hu K, Qiu Y. Efficacy of Second-Generation FLT3 Inhibitors in FLT3-Mutated AML: A Meta-Analysis of Randomized Controlled Trials. Acta Haematologica. 2026:1-12. doi:10.1159/000553180
BibTeX
@article{Yu2026,
author = {Yu, Qili and Cao, Jingni and Chen, Yixia and Ma, Xiongtao and Hu, Kangshuo and Qiu, Yixian},
title = {Efficacy of Second-Generation FLT3 Inhibitors in FLT3-Mutated AML: A Meta-Analysis of Randomized Controlled Trials},
journal = {Acta Haematologica},
year = {2026},
pages = {1--12},
doi = {10.1159/000553180}
}
EUVIMED